CEO Michelle Dipp, OvaScience Inc Insider Buys $1,000,000 of Shares on March, 7, 2014

Michelle Dipp, President & CEO of OvaScience Inc, purchased 100,000 shares of OvaScience Inc (Stock Symbol: Enter OVAS) at $10 per share for a total amount of $1 million on March 7, 2014. OvaScience Inc is located in Cambridge, Massachusetts. On 03/18/2014, OvaScience Inc a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, announced today that the underwriters of its previously announced public offering of common stock have exercised their option to purchase an additional 518,630 shares of common stock at the public offering price of $10.00 per share. As a result, total gross proceeds to OvaScience from this offering are $55.2 million before deducting the underwriting discounts, commissions and estimated expenses. [On 02/27/2014, OvaScience Inc announced its latest annual results. “In 2013, we laid the foundation for the planned international launch of AUGMENTSM, advanced development of new fertility treatments and strengthened our management team,” said Michelle Dipp, M.D., Ph.D., Chief Executive Officer of OvaScience. “We are confident in our ability to deliver AUGMENT to patients in select international IVF clinics in 2014, and prepare for the launch of our newest potential fertility treatment, OvaPrimeSM, in 2015. Research continues on OvaTureSM, a potential hormone-free approach to in vitro fertilization (IVF), and preclinical results which demonstrate that human egg precursor cells can be matured into fertilizable eggs are expected later this year.” According to Capital IQ, OvaScience Inc has a market cap of $181.02 million, an enterprise value of $136.60 million, and trailing 12 month revenues of [Enter $XX million|billion]. OvaScience, Inc., a life sciences company, is engaged in the discovery, development, and commercialization of new treatments for infertility. The company’s patented technology is based on the discovery of egg precursor cells (EggPCs), which are found in the ovaries. It is developing potential next generation in vitro fertilization (IVF) technologies through applying proprietary technology to identify and purify EggPCs. The company has two product candidates in development: OvaTure to create mature fertilizable eggs from a woman’s own EggPCs without the need for hormone injections; and AUGMENT to improve egg quality and increase the success of IVF. The company was formerly known as Ovastem, Inc. and changed its name to OvaScience, Inc. in May 2011. OvaScience, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts. Michelle Dipp’s most recent annual compensation from OvaScience Inc is a salary of $1,500,000, $1,942,620 in other compensation, and a total compensation of $3,442,620. Mrs. Dipp is 36 years old. According to her biography, Dr. Michelle Dipp, M.D., Ph.D., is President, Chief Executive Officer, Director of OvaScience, Inc. She is co-founded the company in April 2011. She has served as a member of the company board of directors since July 2011, the company chief executive officer since June 2011 and the company president since September 2011. Dr. Dipp has served as a partner of Longwood Fund, LP, a venture capital investment fund, since 2010. Through Longwood,she co-founded Verastem, Inc., a biopharmaceutical company, in 2010. From 2008 to 2009, Dr. Dipp served as vice president and then, from 2009 to 2011, senior vice president and head of the Centre of Excellence For External Drug Discovery (CEEDD), a business development unit at GlaxoSmithKline, a pharmaceutical and healthcare company. Prior to that, she was a founding employee of Sirtris Pharmaceuticals, Inc., a pharmaceutical company, where she served as vice president of corporate development from 2005 to 2008. Dr. Dipp serves on the Beth Israel Deaconess Medical Center Board of Trustees. Dr. Dipp holds an M.D. from Oxford University Medical School and a Ph.D. in physiology from the University of Oxford. All stories in DailyStocks.com are for informational purposes only. This is NOT a stock recommendation. This DailyStocks.com story is a daily light analysis featuring a stock with insider buying. With some caveats, insiders purchase a stock because they think the stock is going up. There are other factors to consider such as size of the transaction relative to their compensation and net worth. Sometimes, insiders might be propping a stock price up for future financing. Sometimes, the amount of insider buying are misread or misreported. Each month, DailyStocks releases a a summary of the stocks with insider buying. Sign up for the free monthly newsletter at DailyStocks.com . About Dailystocks.com: DailyStocks.com is the place where you can find stories about stocks with insider buying, where you can educate yourself about stock market investing, and where you can perform the stock search engine analysis – you enter a stock symbol, and you get a resulting page of stock ticker indexed links so that you do not have to type the stock symbol each time.